Cleveland Clinic Top 10 Medical Innovations for 2017 | Liquid Biopsy: #4

Written by: Anna Israyelyan, MD, PhD
Manager, Biopharma Solutions

Published on:
May 23rd, 2017

Anna Israyelyan, MD, PhD
Dr. Israyelyan joined CGI in 2015. She has over 15 years of extensive cancer research and management experience in industry and academia covering wide range of medical areas, including basic, translational, and clinical research. Anna is an active member of the American Society of Hematology (ASH), the American Association for Cancer Research (AACR), and American Association for the Advancement of Science (AAAS). Dr. Israyelyan has a scientific advisory role with matrix management of scientific, technical, and operational aspects related to various biopharma projects and collaborations involving biomarkers in solid tumors and hematologic malignancies.

Liquid biopsies are able to provide information equal to or superior to traditional invasive tumor sampling procedures. With the increased recognition of the power of liquid biopsy technologies, it is no surprise there is an exploding hope, interest, and commitment in the liquid biopsy area.

Cleveland clinic has ranked Liquid Biopsy as #4 on its list of Top 10 Medical Innovations for 2017.

Liquid biopsies are hailed as a flagship technology of the Cancer Moonshot program, an initiative led by former Vice President Joe Biden, to make more therapies available to more patients. With the launch of the Cancer Moonshot, an elite team of academicians, technology leaders, patient advocates, and pharmaceutical experts came together to partner in the Blood Profiling Atlas in Cancer (BloodPAC) project. BloodPAC was launched on October 17, 2016 and aimed to develop a collaborative infrastructure that enables sharing of information between stakeholders in industry, academia, and regulatory agencies. It is essentially an open database of blood-based cancer genomic profiles and analytical methods. BloodPAC will aggregate, make freely available, and harmonize for further analysis, raw datasets, relevant associated clinical data, and sample preparation and handling protocols. BloodPAC’s ultimate goal is to accelerate the timeline to developing safe and effective liquid biopsies that would dramatically improve the lives of cancer patients and their families.

It’s estimated liquid biopsy tests will eventually be a $10 billion market, making it only matter of time before catching and treating cancer is a routine part of your annual checkup.

We have shared with you CGI’s approach to the liquid biopsy trend previously, detailing our solutions for rare cell and cell-free DNA (cfDNA) analysis across multiple platforms. We have also discussed our recent successful CLIA validation and commercial launch of CGI’s next generation sequencing (NGS) assay Liquid::Lung-cfDNA, which detects lung tumor-derived cfDNA obtained from the plasma fraction of blood. At CGI we are constantly innovating around new and existing technologies to further biomarker driven clinical trials and personalized medicine. Liquid::Lung-cfDNA is the latest addition to our burgeoning liquid biopsy test menu and is a testament to CGI’s speedy commitment to innovative and promising technologies such as liquid biopsies.

To learn more about Liquid::Lung-cfDNA as well as CGI’s liquid biopsy approaches in general, or to schedule a conversation with our medical directors and assay development scientists who develop and validate the liquid biopsy tests, please drop me an email. I’d be happy to schedule time to help evaluate and discuss how CGI’s liquid biopsy offerings could be used to meet your clinical trial and drug development needs.

Comments

comments